Fig. 6.

Calcineurin inhibitor blocks Nampt-induced hypertrophy. A: NE or WCL from cardiomyocytes treated with recombinant Nampt or Ad.Nampt were analyzed by Western blot analysis with antibodies as indicated. B: lysates from cardiomyocytes treated with recombinant Nampt (eNampt) or Ad.Nampt in the presence or absence of FK506 were analyzed by Western blot analysis with antibodies as indicated. C: primary cultures of cardiomyocytes labeled with [³H]leucine were treated with 100 ng/ml recombinant Nampt (eNampt) or infected with 10 MOI of Ad.Nampt in the presence or absence of 100 ng/ml FK506. Forty-eight hours after treatment, cells were harvested and incorporation of [³H]leucine into total cellular proteins was measured. D: cardiomyocytes were infected with a NFAT responsive promoter-luciferase reporter adenovirus vector. Twelve hours after infection, cells were treated with recombinant eNampt in the presence or absence of 100 ng/ml FK506. Ad.Nampt virus infection was performed 12 h before NFAT adenovirus infection. E: cardiomyocytes were identified by α-actinin staining, and cardiomyocyte cell size was quantified. Means ± SD; n = 4. *P < 0.001.